119
Participants
Start Date
October 15, 2020
Primary Completion Date
September 30, 2021
Study Completion Date
September 30, 2021
Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
Participants received on-demand treatment, doses range from 30 IU/kg to 50 IU/kg, or doses divided on the discretion of the Investigator.
Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
Participants received prophylaxis treatment at 50 IU/kg every three days.
Capital Medical University affiliated Beijing Children's Hospital, Beijing
The Affiliated Hospital of Xuzhou Medical College, Xuzhou
Anhui Provincial Hospital, Hefei
Jinan central hospital, Ji'nan
The Affiliated Hospital of Qingdao University, Qingdao
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin
Jiangxi Provincial People's Hospital, Nanchang
Fujian Medical University Union Hospital, Fuzhou
Chongqing Three Gorges Central Hospital, Chongqing
Xiangya Hospital of Central South University, Changsha
Henan provincial People's Hospital, Zhengzhou
Henan Cancer Hospital, Zhengzhou
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou
Nanfang Hospital of Southern Medical University, Guangzhou
The Affiliated Hospital of Guizhou Medical University, Guiyang
The First Hospital of Lanzhou University, Lanzhou
The Second Hospital of Shanxi Medical University, Taiyuan
Zhengzhou Gensciences Inc
INDUSTRY